Medexus Pharmaceuticals (MDP) Set to Announce Earnings on Thursday

Medexus Pharmaceuticals (TSE:MDP) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Medexus Pharmaceuticals to post earnings of C$0.03 per share for the quarter.

Medexus Pharmaceuticals (TSE:MDP) last announced its quarterly earnings data on Wednesday, August 7th. The company reported C$0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of C$0.04 by C$0.07. Medexus Pharmaceuticals had a return on equity of 3.95% and a net margin of 1.00%. The business had revenue of C$37.33 million during the quarter, compared to analyst estimates of C$36.95 million.

Medexus Pharmaceuticals Trading Down 1.2 %

Shares of TSE:MDP opened at C$2.55 on Thursday. Medexus Pharmaceuticals has a 1 year low of C$1.44 and a 1 year high of C$3.16. The business has a fifty day simple moving average of C$2.57 and a 200 day simple moving average of C$2.14. The firm has a market cap of C$62.55 million, a price-to-earnings ratio of 51.00 and a beta of 1.96.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Stifel Nicolaus increased their price objective on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Stifel Canada raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Finally, Leede Financial set a C$8.25 target price on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.